CIK: 0000882095
Total reported value
$2.1B
Reporting period: 2026-03-31 · Number of holdings: 6
GILEAD SCIENCES, INC. disclosed 6 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $2.1B and a quarterly turnover rate of 23.9%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "G"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Terms of Use for AI
AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/13f/gilead-sciences-inc
Add ACLXGBX
0.0% $333.5M
Trim RCUS
0.0% -$70.1M
Trim LKFT
0.0% -$49.4M
Trim ASMB
0.0% -$28.2M
Trim KYTX
0.0% -$3.2M
Trim 98422T100
-92.9% -$359.5K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx INC | Stock-Other | 36.44% | +13.80% | — | |
| 2 | RCUS | Arcus Biosciences INC | Stock-Other | 32.05% | -6.64% | — | |
| 3 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 23.67% | -4.78% | — | |
| 4 | ASMB | Assembly Biosciences INC | Stock-Other | 5.90% | -2.02% | — | |
| 5 | KYTX | Kyverna Therapeutics INC | Stock-Other | 1.68% | -0.32% | — | |
| 6 | ✓ | Xilio Therapeutics INC | Stock-Other | 0.26% | -0.04% | -92.86% |
Performance for Q3 2026
—
Performance Last 4 Quarters
—
Based on 0 months of available history
Based on 31% of reported portfolio value with available pricing
Not enough sector-mapped data yet
Gilead Sciences, INC.'s most significant position changes for 2026-03-31: Trim: Xilio Therapeutics INC — shares -92.86%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx INC | +13.8% | — | Unchanged |
| 2 | ✓ | Xilio Therapeutics INC | 0% | -92.86% | Trim |
| 3 | KYTX | Kyverna Therapeutics INC | -0.3% | — | Unchanged |
| 4 | ASMB | Assembly Biosciences INC | -2% | — | Unchanged |
| 5 | LKFT | Lakefront Biotherapeutic-adr | -4.8% | — | Unchanged |
| 6 | RCUS | Arcus Biosciences INC | -6.6% | — | Unchanged |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026 Q1 | 2026-05-08 | 13F-HR | View on EDGAR |
| 2025 Q4 | 2026-02-12 | 13F-HR | View on EDGAR |
| 2025 Q3 | 2025-11-13 | 13F-HR | View on EDGAR |
| 2025 Q2 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025 Q1 | 2025-05-13 | 13F-HR | View on EDGAR |
| 2024 Q4 | 2025-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001085393
Total reported value
$2.1B
108 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001661462
Total reported value
$2.1B
1 stks
2023-12-31
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001454138
Total reported value
$2.1B
18 stks
2026-06-30
AUM within 0.2% of this institution
Institutions with overlapping top holdings
CIK 0001512848
Total reported value
$1.8B
26 stks
2026-03-31
Also holds Arcellx INC as its largest position
CIK 0001855655
Total reported value
$4.9B
35 stks
2026-03-31
Also holds Arcellx INC as its largest position
CIK 0001910264
Total reported value
$915.4M
14 stks
2026-03-31
Also holds Arcellx INC as its largest position
Access Gilead Sciences, INC.'s institutional profile programmatically:
REST API
curl https://alphasmo.com/api/v1/institutions/gilead-sciences-incCLI
npx alphasmo institutions get gilead-sciences-inc